Phase 2 PORT modulator "PORTight": a ctDNA-guided adjuvant radiation enhancer for NSCLC.

This Phase 2 single‐arm trial by Rutgers assesses whether postoperative ctDNA positivity can effectively guide adjuvant treatment decisions—including radiation therapy, chemotherapy, immunotherapy, or targeted therapies—in patients with stage II/III non‐small cell lung cancer. The study also explores radiomic markers from serial CT scans to link imaging features with ctDNA status and refine personalized cancer management.